- Home
- NMAI vs LAB Comparison
NMAI vs LAB Comparison
Compare NMAI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | LAB |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.6M | 488.4M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | NMAI | LAB |
|---|---|---|
| Price | $13.00 | $0.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 107.8K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 44.68 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | $20.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.21 | $0.92 |
| 52 Week High | $13.96 | $1.72 |
Technical Indicators
Market Signals| Indicator | NMAI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 26.69 |
| Support Level | $12.72 | $0.97 |
| Resistance Level | $13.05 | $1.41 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 6.82 | 4.14 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.